The Big Picture: Why We Do What We Do - Antibody-Drug Conjugates (ADCs) in Action

Antibody-Drug Conjugates (ADCs) are complex molecules consisting of three building blocks - (1) antibody, (2) linker and (3) toxin/small molecule (effective moiety). These agents have extensive therapeutic potential and may present significant medical breakthroughs over the coming decade, particularly in cancer treatment. To learn more about how Antibody-Drug Conjugates work in general, watch here.

One such drug is Kadcyla™ (ado-trastuzumab emtansine), the first Genentech antibody-drug conjugate to receive FDA approval. Kadcyla™ harnesses the mechanisms of action of trastuzumab (the antibody in Herceptin™) and the toxin/small molecule DM1. This video shows how this medicine works, in theory.

But theory and practice are two different things. What do patients think? See one woman’s account of how Kadcyla™ has helped improve her quality of life after a disheartening diagnosis.

QPS is gratified that Genentech gave us the opportunity to play a small yet significant role in developing Kadcyla™. Hopefully, our continued involvement by many of the ADC technology platform pioneers in their efforts to develop future generations of ADCs means that we will be able to witness even more bench-to-bedside progress in the future. QPS is proud of the work we do in helping to provide patients with safe, effective and reliable medicines - bottom line, it’s what we’re here for.

20 years in pharma R&D navigation